Cholesterol & Lipid Panel

IFCOR's targeted Cholesterol & Lipid Panel measures the four core cardiovascular risk markers — total cholesterol, LDL (low-density lipoprotein, 'bad' cholesterol), HDL (high-density lipoprotein, 'good' cholesterol), and triglycerides — in a single fasting blood draw priced at 250 Kč all-in. This four-marker panel is the standard cardiovascular risk screen recommended by Czech cardiology guidelines and European Society of Cardiology guidance, giving patients and their physicians the data needed to estimate 10-year cardiovascular event risk, assess the impact of dietary changes, and guide statin therapy decisions. At this price point, it is ideal for frequent monitoring during lipid-lowering interventions.

Dyslipidaemia — abnormal levels of cholesterol fractions and triglycerides in the blood — is one of the strongest modifiable risk factors for atherosclerosis, myocardial infarction, and ischaemic stroke. The four-marker lipid panel at IFCOR Jihlava captures the complete picture needed for cardiovascular risk stratification using the European Heart Score or Czech KV-riziko calculator. Total cholesterol provides the global burden of circulating cholesterol across all lipoprotein fractions. LDL-cholesterol is the primary atherogenic fraction: LDL particles penetrate the arterial intima and become oxidised, triggering foam cell formation and plaque development. Current European guidelines target LDL below 3.0 mmol/L for low-risk individuals, below 2.6 for moderate risk, below 1.8 for high risk, and below 1.4 for very high risk (established cardiovascular disease or familial hypercholesterolaemia). HDL-cholesterol exerts a cardioprotective effect through reverse cholesterol transport — HDL particles collect cholesterol from peripheral tissues and return it to the liver for excretion. HDL below 1.0 mmol/L in men or 1.3 in women is a significant cardiovascular risk amplifier. Triglycerides (fasting measurement is mandatory for accuracy — non-fasting samples can be 30–40% higher due to postprandial lipid peaks) reflect dietary fat intake, carbohydrate excess, insulin resistance, and secondary dyslipidaemia from diabetes, hypothyroidism, or renal disease. Elevated triglycerides above 5.6 mmol/L also create acute pancreatitis risk. The fasting lipid panel is used in sequence: initial baseline → dietary or pharmacological intervention → follow-up at 8–12 weeks to assess response. IFCOR's 250 Kč per-test pricing makes monthly or bimonthly monitoring economically feasible for patients actively managing dyslipidaemia. Results arrive the next business day by secure email.